TARGINIQ Drug Patent Profile

When do Targiniq patents expire, and when can generic versions of Targiniq launch?

Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA.

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

Summary for TARGINIQ

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	1
Patent Applications:	70
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARGINIQ
What excipients (inactive ingredients) are in TARGINIQ?	TARGINIQ excipients list
DailyMed Link:	TARGINIQ at DailyMed

Recent Clinical Trials for TARGINIQ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Turku University Hospital	PHASE3
Helsinki University Central Hospital	PHASE3

See all TARGINIQ clinical trials

US Patents and Regulatory Information for TARGINIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014		DISCN	Yes	No
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014		DISCN	Yes	No

Expired US Patents for TARGINIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014	9,283,221
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014	7,674,799
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-002	Jul 23, 2014	7,683,072
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	9,283,216
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	9,168,252
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-001	Jul 23, 2014	9,205,082
Purdue Pharma Lp	TARGINIQ	naloxone hydrochloride; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205777-003	Jul 23, 2014	8,969,369

International Patents for TARGINIQ

See the table below for patents covering TARGINIQ around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	323491
Australia	2004205244
Australia	2007200253
Australia	2008499
Australia	2009202152
Australia	773642
Brazil	9813827

Supplementary Protection Certificates for TARGINIQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	C300619	Netherlands		PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
1685839	CA 2013 00052	Denmark		PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530
1685839	122013000082	Germany		PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530

Targiniq Market Dynamics and Financial Trajectory: Sales Trends, Exclusivity Risk, Pricing Pressure, and Competitive Threats

Last updated: June 24, 2026

Targiniq’s commercial trajectory is driven by (1) continued demand for extended-release opioid analgesia in labeled indications, (2) payor adoption for the product’s managed-care positioning versus branded and generic alternatives, and (3) a patent and exclusivity clock that determines when pricing pressure accelerates. The near-to-mid term financial picture is therefore a function of uptake in new prescriber panels, pharmacy channel stability, and the timing of generic entry risk.

What is Targiniq and how does it compete in the opioid extended-release market?

Targiniq is an extended-release opioid analgesic. Its market dynamics follow the established pattern for ER opioids: prescriber conversion depends on perceived efficacy and tolerability, payor status depends on contracting and prior authorization dynamics, and revenue durability depends on limiting channel inventory volatility and maintaining differentiated positioning versus immediate-release opioids and ER generics.

How does Targiniq fit payer formularies and pharmacy benefit design?

Commercial adoption in ER opioids typically tracks:

• Step edits and prior authorization for high-daily-dose users
• Quantity limits tied to daily MME (morphine milligram equivalents) policies
• Rebate intensity that increases as competing ER generics expand coverage

How does Targiniq compare with common ER opioid competitors?

In ER opioid categories, competitive pressure generally comes from:

• Branded ER products with negotiated rebates
• Lower-cost ER generics once exclusivity expires
• Therapeutic switching within the opioid class when payors narrow preferred products

For a clean competitive read-through, the key metric is net price trajectory, not list price. ER opioids often show compressed net pricing over time as generic competition expands and as PBMs rebalance preferred tiers.

When do Targiniq lose exclusivity and how does that drive generic entry timing?

Revenue compression risk rises sharply when exclusivity and patent barriers fall, enabling either:

• ANDA-based generic launches (for small molecules) or
• Bioequivalent competition if applicable, though opioid ER products are generally small-molecule ANDAs
• “At-risk” launches after Paragraph IV challenges (if litigation settles or fails)

The pace of generic entry is usually governed by:

• Patent expiration dates covering key formulations, extended-release technology, and manufacturing
• Orange Book-listed patents and whether they withstand challenges
• Settlement agreements that delay launch dates

What patents protect Targiniq and what is the strength of the patent estate?

Patent estates for ER opioids typically include multiple layers:

• Composition-of-matter claims covering the active ingredient or its salts
• Formulation patents covering ER matrix, coating, bead design, or delivery kinetics
• Method-of-use claims tied to specific dosing regimens or pain management protocols
• Manufacturing process patents tied to specific steps and critical parameters

For market planning, the practical question is not “how many patents exist” but whether:

• Orange Book listing creates enforceable barriers for ANDA filers
• Expiration timing staggers or clusters
• Litigation or terminal disclaimers collapse the effective barrier early

What is the Orange Book status of Targiniq?

Orange Book status determines how ANDA applicants can structure a challenge strategy:

• Whether the active ingredient is covered by listed patents
• Whether formulation patents list specific dosage forms or strengths
• Whether method-of-use patents are listed and how they can be attacked

The Orange Book listing also predicts the likelihood of Paragraph IV filings, which in turn drives litigation frequency and potential settlement delays.

What patent litigation affects Targiniq generic entry and settlement risk?

Patent litigation shapes financial outcomes through:

• Launch delay from settlements
• Temporary injunction risk following court decisions
• Uncertainty premiums that influence PBM switching and inventory planning

For ER opioids, settlements often result in:

• Delayed generic launch dates
• Carve-outs for certain strengths or patient segments
• Cross-licenses or no-entry agreements with stipulated timing

The strongest driver of revenue trajectory is whether Targiniq faces one or multiple generic entrants and at what time horizons.

How many Paragraph IV challenges exist for Targiniq and what launch scenarios follow?

Paragraph IV challenge volume predicts competitive intensity:

• Single challenger: may delay switching but can still pressure net pricing once launch occurs
• Multiple challengers: increases entry probability for broader pharmacy coverage and accelerates rebate compression

Launch scenarios that affect revenue:

1. “Authorized generic” style entry (if applicable) that compresses net pricing immediately
2. Limited-strength entry that still triggers payer formulary redesign
3. Rapid multi-strength generic competition that forces step-therapy tightening and substitution

What formulations are protected by Targiniq patents and how does that restrict “skinny labeling” substitutes?

ER products often have dosage-form-specific barriers. Formulation patent coverage can prevent:

• Easy design-around
• Partial equivalence strategies
• Strength-by-strength substitution that might otherwise reduce payer switching friction

If patent coverage is tight around ER technology, generic entrants may need additional time for formulation development and regulatory bridging, extending effective exclusivity beyond the earliest listed expiration.

How does Targiniq pricing evolve over time under ER opioid payer pressure?

Pricing trajectory in ER opioids usually trends downward on a net basis:

• Early-stage pricing is supported by differentiation and prescriber adoption
• Mid-stage pricing compresses as rebates increase and coverage narrows
• Late-stage pricing accelerates downward around generic launches and preferred-tier consolidation

Financial trajectory is therefore best assessed through net sales and pharmacy-level demand, with special attention to:

• Share of prescriptions across ER strength bands
• Contracting outcomes with PBMs
• Channel inventory changes that can temporarily inflate reported sales before sustained decline

What is the competitive landscape for Targiniq and which companies are positioned to take share?

Competitive landscape for ER opioids typically includes:

• Branded incumbents with established payer relationships
• Generic manufacturers with ANDA filings aligned to patent cliffs
• PBM-aligned preferred generics that can shift coverage rapidly once permitted

The highest-risk competitors are those with:

• Multiple ANDA approvals ready to launch quickly
• Established distribution in ER opioid channels
• Prior launch histories that indicate payer switching playbooks

How does Targiniq compare with other opioid extended-release drugs on market durability?

Durability hinges on:

• Strength coverage breadth (how many strengths remain protected or differentiation-supported)
• Patient retention: switch costs, prescriber familiarity, and prior authorization hurdles
• Litigation calendar: whether the product clears patent risk through staggered expirations or faces a concentrated entry window

In ER opioids, market share often shifts quickly once generics are available across most strengths and when payors remove preferred-tier exceptions.

What FDA regulatory milestones affect Targiniq revenue, such as new strengths or labeling changes?

FDA activity can affect sales even without generic competition:

• Label expansions that broaden eligible patient groups
• Safety-related label updates that change dosing practices or duration of use
• REMS requirements for opioids that can affect prescriber behavior and patient throughput

For ER opioid products, labeling consistency is closely tied to prescriber switching and payer coverage stability.

What generic entry risks exist for Targiniq in the US?

US generic entry risk is determined by:

• Whether Orange Book-listed patents cover the specific strength and dosage form
• Whether those patents expire before or after potential design-around timelines
• Whether ANDA applicants file Paragraph IV certifications for the relevant patents
• Litigation outcomes and settlement timing

The financial implication is nonlinear: risk usually appears in the quarter(s) where payors begin formulary changes and where channel inventory normalizes ahead of launch.

What is the likely financial trajectory for Targiniq under an exclusivity-to-generic transition model?

Targiniq’s financial trajectory typically follows a staged pattern common to mid-life branded ER opioids:

1. Growth or stability phase supported by prescriber adoption and formulary access
2. Pricing pressure onset as payer rebates rise and coverage narrows
3. Margin compression and volume substitution once generic entry begins
4. Post-entry stabilization depending on market share distribution among entrants

Financial outcomes depend on:

• The speed of payer conversion from Targiniq to generic ER versions
• The number of entrants at launch
• Strength-by-strength availability and how quickly the full spectrum of strengths is covered

Key Takeaways

• Targiniq’s revenue path is dominated by ER opioid payer contracting, net price compression dynamics, and the timing of exclusivity and patent barriers.
• Generic entry risk concentrates around patent cliffs tied to Orange Book-listed formulation and related ER-technology coverage.
• The competitive impact is nonlinear: revenue pressure typically accelerates as payors tighten preferred tiers and as channel inventory normalizes around launches.
• Litigation and settlement timing are the major determinants of when pricing pressure turns from gradual to immediate.

FAQs

1) What drives net sales changes for Targiniq after payer formulary updates?
Net sales usually shift with preferred tier status, prior authorization tightening, and rebate-driven net price changes that alter patient switching behavior.

2) How does the number of generic entrants affect Targiniq’s post-launch sales decline?
More entrants generally increase rebate competition, expand coverage across strengths, and accelerate payer switching, deepening and shortening the decline curve.

3) Do formulation patents for ER opioids materially delay generic launches?
Yes, formulation and ER technology patents can force slower design-around or bridging work, delaying full-strength availability and limiting immediate substitution.

4) What is the most important indicator that generic pressure is imminent for Targiniq?
Quarter-to-quarter net price compression combined with formulary and step-therapy changes that signal channel conversion behavior.

5) How do patent settlements typically shape the timing of Targiniq generic competition?
Settlements commonly lock in delayed launch dates and can restrict certain strengths, turning immediate competition into a staggered transition.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. U.S. Food and Drug Administration. Drug Trials Snapshots (drug labeling and approval milestones). https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
3. FDA. Approved opioids and REMS-related information. https://www.fda.gov/drugs/drug-safety-and-availability/drug-rems-restricted-access-programs